Clinical trial · Interventional
Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors
Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors, A Randomized Multicentric Controlled Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Experienced anesthesiologists often attempt to anticipate and blunt the hypertensive responses seen in varying degrees at critical moments of surgical stimulation. Additionally, it may take a long time to treat acute intraoperative hypertension using anesthetics, and there may be a subsequent period of hypotension due to over-compensation. Most practicing anesthesiologists rely on antihypertensive drugs for the rapid control of elevated arterial blood pressure, when volatile anesthetics and narcotics need to be discontinued for awakening. Relatively high doses of antihypertensive drugs, such as labetalol, nicardipine, or esmolol, are commonly used, regardless of the anesthetic technique.One of the main methods to control arterial blood pressure intraoperatively, was to use a typical antihypertensive regimen on an as-needed basis as well as common methods; adjustments in the concentration of volatile anesthetic.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Neoplasms | Thyroid Gland Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dexmedetomidine Injection [Precedex] | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- labetalol Group (Control group)
- description
- where patients will receive an initial bolus dose of labetalol 20 mg by slow IV injection over a 2-minute period before surgical incision to achieve target hemodynamics. Additional injections of 40 to 80 mg can be given on demand at 10-minute intervals until a desired supine blood pressure is achieved or a total of 300 mg has been used then continuous infusion of diluted labetalol solution will be administered at a rate of 2 mL/min to deliver 2 mg/min to control BP swings intraoperatively.
- interventionNames
- Drug: Dexmedetomidine Injection [Precedex]
- type
- ACTIVE_COMPARATOR
- label
- Dexmedetomidine group (Active Group);
- description
- where patients will receive an iv-bolus dose of 0.5-1 μg/kg of dexmedetomidine over 10 min before surgical incision followed by IV infusion of 0.2 - 0.7 μg/kg/h to control BP intraoperatively.
- interventionNames
- Drug: Dexmedetomidine Injection [Precedex]
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients subjected to thyroid resection surgeries for active thyroid tumors. * The enrolled age will be from 20 years to 65 years * ASA, I-III and NYHA, I-II. Exclusion Criteria: * ASA physical status \>III and NYHA \>II, * body mass index \>40 kg/m2, * pregnant women, * preoperative opioid consumption, * Allergy to dexmedetomidine * Contraindications as hypotension or cardiovascular compromise * Unwilling to participate in the study
References
Publications (0)
Data not yet available